9:20 am Chair’s Opening Remarks

Optimizing ADC Dosage to Minimize Toxicity, while Maximizing Efficacy & Improve Therapeutic Windows

9:30 am Incorporating Mitigation Strategies into Your Clinical Trial Design to Increase Your Dosage


  • Discovering what you can do to manage toxicities in the clinic will allow for higher dosing for your ADC
  • Hearing about most common toxicities and how these have been managed in previous case studies
  • Discussing the severity of certain toxicities and the risks of relying on mitigation in the clinic

10:00 am Potential Mechanism of PBD Conjugate-Associated Fluid Retention in Patients


  • Reviewing of AEs of effusions and edema in patients treated with various PBD conjugates
  • Presenting toxicity findings in NHPs dosed with tool PBD compounds
  • Hypothesizing the mechanism of fluid retention in patients

10:30 am The Utility of Clinical Biomarker Data for ADC Dose Selection


  • Looking at how clinical biomarker data can be used to inform your dose selection and escalation
  • Guiding dose response using an improved understanding of response
  • Identifying clinical biomarkers for monitoring dose response

11:00 am Morning Refreshments & Networking

Advancing ADC Designs for Ideal Linker Stability & Antibody-Payload Ratio

11:30 am Identifying Conjugation Sites & Impacts of Bioconjugation Method/ DAR on FC Binding on ADC Toxicity Profiles


  • Approaching your conjugation site identification
  • Outlining the impacts of the bioconjugation method on Fc binding
  • Discussing the implications of ADC design on tox profiles

12:00 pm Tumor Selective Linker Design to Optimize Therapeutic Index of ADCs

  • Jutta Deckert Executive Director - Translational Research & Development, Iksuda Therapeutics


  • Linker chemistry for effective conjugation and payload release
  • Delving deeper into the linker-payload selection to balance safety and efficacy
  • Matching linker-payload to targets to mitigate off- and on-target toxicities

12:30 pm Optimizing Linker Stability in ADC Design to Maximize Efficacy

  • Stuart Barnscher Director, Preclinical Programs, ADC Therapeutic Development, Zymeworks


  • Finding the sweet spot between too reactive and not reactive enough
  • Benefits of not having a linker that is too stable
  • Testing for optimal linker stability to reduce off-target effects

1:00 pm Lunch & Networking

Discovering the Next-Generation of ADCs & Related Toxicities

2:00 pm Beyond Cell Killing Payloads: ADCs for Alternate Clinical Indications

  • Nathan Alves Associate Professor, Indiana University School of Medicine


  • Looking into current research on non-cell killing payloads
  • Identifying toxicological benefits of non-cell killing payloads
  • Thinking about the future of novel ADCs

2:30 pm Building an ADC platform with Amanitin as a new payload and a novel mode of action

  • Kristin Decker Associate Director Pharmacology & Toxicology, Heidelberg Pharma GmbH


  • Understanding the toxicity profile associated with the use of amatoxins as novel ADC payloads
  • Optimizing the ADC technology towards Amanitin-based ADCs with a good therapeutic index
  • Possibilities to optimize the therapeutic index of Amanitin-based ADCs by the route and schedule of administration 

3:00 pm Panel: Learning from Previous ADC Development: What Can we Learn from Previous ADCs That Can Be Applied to Novel ADCs?


  • Have we learned any lessons in the development of ADCs that we need to consider when developing novel ADCs?
  • What are the toxicological considerations associated with developing novel ADCs?
  • What are the preclinical and clinical challenges in developing novel ADCs?

3:45 pm End of ADC Toxicity Summit